ScholarLens Back to search
2011•The Chinese Journal of Clinical PharmacologyRequires access

Assessing the effects of piperacillin/sulbactam in the treatment of ventilator-associated pneumonia

Hongquan Zhang

Open publisher page 0 citations

Abstract

Objective To evaluate the reliability of piperacillin/sulbactam on the patients with ventilator-associated pneumonia(VAP) with clinical efficacy and bacterial clearance rate.Methods A total of 106 patients with VAP were enrolled into this clinical study,including 50 cases in piperacillin/sulbactam group(PSB group) and 56 cases in piperacillin/ tazobactam group(PTZ group).The clinical efficacy and bacterial clearance rate of piperacillin/sulbactam and piperacillin/tazobactam in the treatment of VAP were prospectively analyzed during the period of Oct 2009 to Oct 2010.Results The cure and effective rates were 46.0% and 76.0% in the PSB group and 48.2% and 76.8% in the PTZ group,respectively.Conclusion Piperacillin/sulbactam is as effective as piperacillin/tazobactam for the treatment of VAP.Piperacillin/sulbactam exhibits good activity again common strains isolated from VAP.

About this research paper

What this paper is about

Objective To evaluate the reliability of piperacillin/sulbactam on the patients with ventilator-associated pneumonia(VAP) with clinical efficacy and bacterial clearance rate.Methods A total of 106 patients with VAP were enrolled into this clinical study,including 50 cases in piperacillin/sulbactam group(PSB group) and 56 cases in piperacillin/ tazobactam group(PTZ group).The clinical efficacy and bacterial clearance rate of piperacillin/sulbactam and piperacillin/tazobactam in the treatment of VAP were prospectively analyzed during the period of Oct 2009 to Oct 2010.Results The cure and effective rates were 46.0% and 76.0% in the PSB group and 48.2% and 76.8% in the PTZ group,respectively.Conclusion Piperacillin/sulbactam is as effective as piperacillin/tazobactam for the treatment of VAP.Piperacillin/sulbactam exhibits good activity again common strains isolated from VAP.

Why it matters

A significance statement is not available in the OpenAlex record.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

Objective To evaluate the reliability of piperacillin/sulbactam on the patients with ventilator-associated pneumonia(VAP) with clinical efficacy and bacterial clearance rate.Methods A total of 106 patients with VAP were enrolled into this clinical study,including 50 cases in piperacillin/sulbactam group(PSB group) and 56 cases in piperacillin/ tazobactam group(PTZ group).The clinical efficacy and bacterial clearance rate of piperacillin/sulbactam and piperacillin/tazobactam in the treatment of VAP were prospectively analyzed during the period of Oct 2009 to Oct 2010.Results The cure and effective rates were 46.0% and 76.0% in the PSB group and 48.2% and 76.8% in the PTZ group,respectively.Conclusion Piperacillin/sulbactam is as effective as piperacillin/tazobactam for the treatment of VAP.Piperacillin/sulbactam exhibits good activity again common strains isolated from VAP.

Key concepts: Piperacillin, Sulbactam, Piperacillin/tazobactam, Medicine, Tazobactam, Ventilator-associated pneumonia, Internal medicine, Pneumonia

Related papers

Related paper 1Related paper 2Related paper 3
Back to paper searchBrowse research topicsOriginal source
Assessing the effects of piperacillin/sulbactam in the treatment of ventilator-associated pneumonia — Research Paper | ScholarLens